- New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide
- Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya
- Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, forms of the condition where treatment options are limited
BASEL, Switzerland I March 13, 2013 I New data will be presented at the 65th annual meeting of the American Academy of Neurology (AAN) that show continued innovation within the Novartis Multiple Sclerosis (MS) portfolio[1]. Growing clinical trial and real-world experience with Gilenya® (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS (RMS),will be highlighted[2-7]. Updates on studies of Gilenya in people with primary-progressive MS (PPMS)[8] and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS (SPMS) will also be communicated[9].
"Novartis is pleased to present new data that underscore Gilenya’s pioneering role in the treatment of MS," said Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals AG. "These results, as well as updates on our investigational MS compound BAF312 (siponimod) show that we are making real progress in our commitment to address unmet medical need in MS and to provide a treatment at every stage of the disease."
Data from three large Phase III studies will highlight the efficacy of Gilenya in reducing the rate of brain volume loss[2], the best characterized magnetic resonance imaging (MRI) predictor of long-term disability. There will also be a presentation on the INFORMS study, which is evaluating Gilenya in patients with PPMS[8]. This form of MS affects about 10% of people with MS and follows a steady course of worsening neurologic function for which there are no approved disease modifying treatments[12].
Additional data will showcase Gilenya’s high efficacy and well characterized and manageable safety profile[4,10,11].Latest information shows that the growing real-world and clinical trial experience base for Gilenya now encompasses more than 50,000 patients and 60,000 patient years of exposure worldwide[13].
New details will be provided on the design of a Phase III study evaluating the efficacy, safety and tolerability of BAF312 (siponimod) in patients with SPMS, which is a sub-type of MS where there are limited treatment options[9]. The vast majority (85%) of people with relapsing-remitting MS will transition to SPMS; 50% within 10 years of disease onset and 90% within 25 years[14].
During the AAN congress, Novartis will present a Corporate Therapeutic Update, "The Gilenya Experience: A Focus on the Patient in Clinical Practice," on Tuesday 19 March at 19:00 – 22:00 PDT at the San Diego Marriott Marquis. Novartis will also host a Patient Advocacy Forum.
Additionally, to support the exchange of educational information within the MS community, the Novartis exhibit at the congress will showcase an expanded Gilenya online and social media platform including the new Gilenya Facebook and GilenyaGo Twitter accounts, YouTube channel, and Gilenya.com mobile site.
Novartis MS portfolio highlights at AAN include:
Gilenya (fingolimod) in relapsing-remitting MS
Fingolimod – effect on brain atrophy and clinical/MRI correlations in three Phase III studies – TRANSFORMS, FREEDOMS and FREEDOMS II. Platform presentation, S51.006 Cohen: 21 March, 15:15 hrs. PDT.
Fingolimod reduces annualized relapse rate in patients with relapsing-remitting multiple sclerosis: FREEDOMS II study subgroup analysis. Poster P07.102, Goodin: 21 March, 14:00 hrs. PDT.
Long-term safety of fingolimod in patients with relapsing-remitting multiple sclerosis. Results from Phase III FREEDOMS extension study. Poster P01.165, Vollmer: 18 March, 14:00 hrs. PDT.
Effect of switching from intramuscular interferon b-1a to fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Poster P07.107, Meng: 21 March, 14:00 hrs. PDT.
Effects of fingolimod on disability progression in patients with disability as measured by EDSS at baseline: post-hoc analyses of FREEDOMS I and II. Poster P04.128, Bergvall: 20 March, 07:30 hrs. PDT.
Fingolimod observational studies program in patients with relapsing-remitting multiple sclerosis: Study designs. Poster P07.100, Butzkueven: 21 March, 14:00 hrs. PDT.
Gilenya (fingolimod) in primary progressive MS
Study design and baseline characteristics of the INFORMS study: Fingolimod in patients with primary progressive multiple sclerosis. Poster P07.116, Miller: 21 March, 14:00 hrs. PDT.
BAF312 (siponimod) in secondary-progressive MS
Siponimod (BAF312) for the treatment of secondary-progressive multiple sclerosis: design of the Phase III EXPAND trial. Poster P07.126, Kappos: 21 March, 14:00 hrs. PDT.
In addition to marketed products Gilenya and Extavia® (interferon beta-1b for subcutaneous injection) the Novartis MS portfolio includes investigational compounds BAF312 (siponimod), and AIN457 (secukinumab), a fully human monoclonal antibody inhibiting interleukin-17A (IL-17A), a key pro-inflammatory cytokine.
About Gilenya
Gilenya is the first oral therapy approved to treat relapsing forms of MS and the first in a new class of compounds called sphingosine 1-phosphate receptor modulators[15,16]. Gilenya is thought to act on inflammatory processes implicated in the MS disease process[15,16].
Data has shown significant efficacy with Gilenya in reducing relapses and significant slowing of six-month disability progression sustained at four years[17]. Nearly half of Gilenya patients were disease-free after one year of treatment[18] and in the pivotal FREEDOMS study eight out of ten patients remained on treatment at two years[10]. Gilenya is the only oral treatment shown to consistently decrease brain volume loss, the best characterized magnetic resonance imaging (MRI) predictor of long-term disability.
Gilenya has demonstrated superior efficacy compared to Avonex® (interferon beta-1a IM), a commonly prescribed treatment, showing a 52% relative reduction in annualized relapse rate (primary endpoint) at one year in a pivotal head-to-head trial in patients with relapsing-remitting multiple sclerosis[11]. In a post hoc sub-group analysis, Gilenya showed a 61% relative reduction in annualized relapse rate compared to interferon-beta-1a (IM) at one year in subgroups of patients with highly active relapsing-remitting MS not responding to interferon treatment[19].
In clinical trials, Gilenya was generally well-tolerated with a manageable safety profile. The most common side effects were headache, liver enzyme elevations, influenza, diarrhea, back pain, and cough. Other Gilenya-related side effects included transient, generally asymptomatic, heart rate reduction and atrioventricular block upon treatment initiation, mild blood pressure increase, macular edema and mild bronchoconstriction[10,11]. The rates of infections overall, including serious infections, were comparable among treatment groups, although a slight increase in lower respiratory tract infections (primarily bronchitis) was seen in patients treated with Gilenya. The number of malignancies reported across the clinical trial program was small, with comparable rates between the Gilenya and control groups[10,11].
Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation.
About BAF312 (siponimod)
BAF312 (siponimod) is an investigational compound in the Novartis Multiple Sclerosis (MS) portfolio. BAF312 is an oral, selective modulator of the sphingosine 1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1, 5R modulator) with a short half-life leading to relatively rapid washout (6 days)[20]. The short half-life allows for a rapid recovery of blood lymphocyte counts following treatment discontinuation[21]. In the Phase II BOLD study, BAF312 demonstrated a favorable safety and tolerability profile when an initial dose titration regimen was used at the start of treatment. The most common adverse events were headache, bradycardia, dizziness and nasopharyngitis[21].
SOURCE: Novartis
Post Views: 66
- New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide
- Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya
- Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, forms of the condition where treatment options are limited
BASEL, Switzerland I March 13, 2013 I New data will be presented at the 65th annual meeting of the American Academy of Neurology (AAN) that show continued innovation within the Novartis Multiple Sclerosis (MS) portfolio[1]. Growing clinical trial and real-world experience with Gilenya® (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS (RMS),will be highlighted[2-7]. Updates on studies of Gilenya in people with primary-progressive MS (PPMS)[8] and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS (SPMS) will also be communicated[9].
"Novartis is pleased to present new data that underscore Gilenya’s pioneering role in the treatment of MS," said Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals AG. "These results, as well as updates on our investigational MS compound BAF312 (siponimod) show that we are making real progress in our commitment to address unmet medical need in MS and to provide a treatment at every stage of the disease."
Data from three large Phase III studies will highlight the efficacy of Gilenya in reducing the rate of brain volume loss[2], the best characterized magnetic resonance imaging (MRI) predictor of long-term disability. There will also be a presentation on the INFORMS study, which is evaluating Gilenya in patients with PPMS[8]. This form of MS affects about 10% of people with MS and follows a steady course of worsening neurologic function for which there are no approved disease modifying treatments[12].
Additional data will showcase Gilenya’s high efficacy and well characterized and manageable safety profile[4,10,11].Latest information shows that the growing real-world and clinical trial experience base for Gilenya now encompasses more than 50,000 patients and 60,000 patient years of exposure worldwide[13].
New details will be provided on the design of a Phase III study evaluating the efficacy, safety and tolerability of BAF312 (siponimod) in patients with SPMS, which is a sub-type of MS where there are limited treatment options[9]. The vast majority (85%) of people with relapsing-remitting MS will transition to SPMS; 50% within 10 years of disease onset and 90% within 25 years[14].
During the AAN congress, Novartis will present a Corporate Therapeutic Update, "The Gilenya Experience: A Focus on the Patient in Clinical Practice," on Tuesday 19 March at 19:00 – 22:00 PDT at the San Diego Marriott Marquis. Novartis will also host a Patient Advocacy Forum.
Additionally, to support the exchange of educational information within the MS community, the Novartis exhibit at the congress will showcase an expanded Gilenya online and social media platform including the new Gilenya Facebook and GilenyaGo Twitter accounts, YouTube channel, and Gilenya.com mobile site.
Novartis MS portfolio highlights at AAN include:
Gilenya (fingolimod) in relapsing-remitting MS
Fingolimod – effect on brain atrophy and clinical/MRI correlations in three Phase III studies – TRANSFORMS, FREEDOMS and FREEDOMS II. Platform presentation, S51.006 Cohen: 21 March, 15:15 hrs. PDT.
Fingolimod reduces annualized relapse rate in patients with relapsing-remitting multiple sclerosis: FREEDOMS II study subgroup analysis. Poster P07.102, Goodin: 21 March, 14:00 hrs. PDT.
Long-term safety of fingolimod in patients with relapsing-remitting multiple sclerosis. Results from Phase III FREEDOMS extension study. Poster P01.165, Vollmer: 18 March, 14:00 hrs. PDT.
Effect of switching from intramuscular interferon b-1a to fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Poster P07.107, Meng: 21 March, 14:00 hrs. PDT.
Effects of fingolimod on disability progression in patients with disability as measured by EDSS at baseline: post-hoc analyses of FREEDOMS I and II. Poster P04.128, Bergvall: 20 March, 07:30 hrs. PDT.
Fingolimod observational studies program in patients with relapsing-remitting multiple sclerosis: Study designs. Poster P07.100, Butzkueven: 21 March, 14:00 hrs. PDT.
Gilenya (fingolimod) in primary progressive MS
Study design and baseline characteristics of the INFORMS study: Fingolimod in patients with primary progressive multiple sclerosis. Poster P07.116, Miller: 21 March, 14:00 hrs. PDT.
BAF312 (siponimod) in secondary-progressive MS
Siponimod (BAF312) for the treatment of secondary-progressive multiple sclerosis: design of the Phase III EXPAND trial. Poster P07.126, Kappos: 21 March, 14:00 hrs. PDT.
In addition to marketed products Gilenya and Extavia® (interferon beta-1b for subcutaneous injection) the Novartis MS portfolio includes investigational compounds BAF312 (siponimod), and AIN457 (secukinumab), a fully human monoclonal antibody inhibiting interleukin-17A (IL-17A), a key pro-inflammatory cytokine.
About Gilenya
Gilenya is the first oral therapy approved to treat relapsing forms of MS and the first in a new class of compounds called sphingosine 1-phosphate receptor modulators[15,16]. Gilenya is thought to act on inflammatory processes implicated in the MS disease process[15,16].
Data has shown significant efficacy with Gilenya in reducing relapses and significant slowing of six-month disability progression sustained at four years[17]. Nearly half of Gilenya patients were disease-free after one year of treatment[18] and in the pivotal FREEDOMS study eight out of ten patients remained on treatment at two years[10]. Gilenya is the only oral treatment shown to consistently decrease brain volume loss, the best characterized magnetic resonance imaging (MRI) predictor of long-term disability.
Gilenya has demonstrated superior efficacy compared to Avonex® (interferon beta-1a IM), a commonly prescribed treatment, showing a 52% relative reduction in annualized relapse rate (primary endpoint) at one year in a pivotal head-to-head trial in patients with relapsing-remitting multiple sclerosis[11]. In a post hoc sub-group analysis, Gilenya showed a 61% relative reduction in annualized relapse rate compared to interferon-beta-1a (IM) at one year in subgroups of patients with highly active relapsing-remitting MS not responding to interferon treatment[19].
In clinical trials, Gilenya was generally well-tolerated with a manageable safety profile. The most common side effects were headache, liver enzyme elevations, influenza, diarrhea, back pain, and cough. Other Gilenya-related side effects included transient, generally asymptomatic, heart rate reduction and atrioventricular block upon treatment initiation, mild blood pressure increase, macular edema and mild bronchoconstriction[10,11]. The rates of infections overall, including serious infections, were comparable among treatment groups, although a slight increase in lower respiratory tract infections (primarily bronchitis) was seen in patients treated with Gilenya. The number of malignancies reported across the clinical trial program was small, with comparable rates between the Gilenya and control groups[10,11].
Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation.
About BAF312 (siponimod)
BAF312 (siponimod) is an investigational compound in the Novartis Multiple Sclerosis (MS) portfolio. BAF312 is an oral, selective modulator of the sphingosine 1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1, 5R modulator) with a short half-life leading to relatively rapid washout (6 days)[20]. The short half-life allows for a rapid recovery of blood lymphocyte counts following treatment discontinuation[21]. In the Phase II BOLD study, BAF312 demonstrated a favorable safety and tolerability profile when an initial dose titration regimen was used at the start of treatment. The most common adverse events were headache, bradycardia, dizziness and nasopharyngitis[21].
SOURCE: Novartis
Post Views: 66
